Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Gains from Sales and Divestitures (2020 - 2023)

Historic Gains from Sales and Divestitures for Terns Pharmaceuticals (TERN) over the last 3 years, with Q3 2023 value amounting to $34762.0.

  • Terns Pharmaceuticals' Gains from Sales and Divestitures changed N/A to $34762.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $34762.0, marking a year-over-year change of. This contributed to the annual value of $71429.0 for FY2021, which is 1428.49% down from last year.
  • Latest data reveals that Terns Pharmaceuticals reported Gains from Sales and Divestitures of $34762.0 as of Q3 2023.
  • Terns Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $83333.0 for Q4 2020, and its period low was $27055.0 during Q2 2023.
  • Its 3-year average for Gains from Sales and Divestitures is $59906.2, with a median of $71429.0 in 2021.
  • The largest annual percentage gain for Terns Pharmaceuticals' Gains from Sales and Divestitures in the last 5 years was 1428.49% (2021), contrasted with its biggest fall of 1428.49% (2021).
  • Over the past 3 years, Terns Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $83333.0 in 2020, then decreased by 14.28% to $71429.0 in 2021, then crashed by 51.33% to $34762.0 in 2023.
  • Its last three reported values are $34762.0 in Q3 2023, $27055.0 for Q2 2023, and $71429.0 during Q4 2021.